Related Experiment Video

Updated: Dec 24, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.7K

Late Administration of Surfactant May Increase the Risk of Patent Ductus Arteriosus

Fuat Emre Canpolat1, Gülsüm Kadıoğlu Şimşek1, James Webbe2

  • 1NICU, Department of Neonatology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.

Frontiers in Pediatrics
|April 17, 2020
PubMed

Insights

Late surfactant administration in preterm infants increases the risk of developing patent ductus arteriosus (PDA). Early surfactant delivery is crucial for better neonatal outcomes.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Respiratory Medicine

Background:

  • Surfactant therapy is vital for preterm infants.
  • Early surfactant administration is most effective but not always achieved.
  • Delayed surfactant may be linked to neonatal complications.

Purpose of the Study:

  • To investigate the association between surfactant administration timing and patent ductus arteriosus (PDA).
  • To explore the relationship between delayed surfactant and other neonatal morbidities.

Main Methods:

  • Retrospective analysis of 819 preterm infants (<30 weeks gestational age, <1500g).
  • Infants categorized into early (<2h) and late (>2h) surfactant groups.
  • Statistical analysis including multinominal logistic regression.

Main Results:

  • PDA detected in 48% of early group vs. 74% of late group (p=0.001).
  • Late surfactant administration (OR 3.5, 95% CI 2.2-5.64) significantly increased PDA risk (p=0.001).

Conclusions:

  • Late surfactant administration is associated with a significantly higher risk of developing PDA.
  • Optimizing surfactant timing is critical in neonatal care for preterm infants.

Keywords:
early rescuepatent ductus arteriosuspreterm infantrespiratory distress syndromesurfactant

More Related Videos

Intratracheal Instillation of Stem Cells in Term Neonatal Rats04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

6.0K
Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS

Published on: September 7, 2016

11.5K

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
63.9K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
816
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
2.8K
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
661
Factors Affecting Pulmonary Ventilation01:19

Factors Affecting Pulmonary Ventilation

Besides the pressure difference between the external environment and the lungs, the airflow rate and ease of pulmonary ventilation are also influenced by three other factors: surface tension of the fluid in the alveoli, compliance of the lungs, and airway resistance.
Alveolar Surface Tension
The alveolar fluid lines the luminal surface of the alveoli and exerts a force called surface tension. This force is caused by the polar water molecules in the liquid being more strongly attracted to each...
2.6K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
372